Гиппократ не рад. Путеводитель в мире медицинских исследований

104. Stroes, E. S. et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 36, 1012–22 (2015).

105. Kashani, A. et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114, 2788–97 (2006).

106. Riaz, H. et al. Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance. Am. J. Cardiol. 120, 774–781 (2017).

107. McGuinness, B., Craig, D., Bullock, R. & Passmore, P. Statins for the prevention of dementia. Cochrane Database Syst. Rev. (2016). doi:10.1002/14651858.CD003160.pub3

108. O’Donoghue, M. et al. Lipoprotein-Associated Phospholipase A 2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy – Thrombolysis In Myocardial Infarction) Trial. Circulation 113, 1745–1752 (2006).

109. Taylor, F. et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. (2013). doi:10.1002/14651858.CD004816.pub5

110. Silva, M. A., Swanson, A. C., Gandhi, P. J. & Tataronis, G. R. Statin-related adverse events: A meta-analysis. Clin. Ther. 28, 26–35 (2006).

111. Finegold, J. A., Manisty, C. H., Goldacre, B., Barron, A. J. & Francis, D. P. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur. J. Prev. Cardiol. 21, 464–474 (2014).

112. Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486–541 (2018).